Recurrent Viral Liver Disease (Hepatitis B and C) after Liver Transplantation

Marco Antonio Olivera-Martínez, Juan F. Gallegos-Orozco

Research output: Contribution to journalReview article

16 Citations (Scopus)

Abstract

Hepatitis C represents more than 35% of liver transplant candidates worldwide. Meanwhile, hepatitis B continues to be an important cause of end-stage liver disease and hepatocellular carcinoma in Asia and Africa. Recurrent viral liver disease is a significant event after liver transplantation and continues to be one of the main causes of graft dysfunction and loss in the middle and long-term follow-up. Mechanisms of liver reinfection and disease recurrence vary between these two viruses and pre-emptive as well as the therapeutic approaches are different. Hepatitis B patients can be managed with immune globulin immediately after liver transplant and various agents such as nucleotide and nucleoside analogues can be associated. As a result, disease recurrence has been delayed or prevented in these patients. Individuals transplanted for hepatitis C are known to have universal reinfection and a high rate of disease recurrence has been reported in the literature. Strategies to treat hepatitis C recurrence are limited to the use of pegylated interferon and ribavirin when disease is demonstrated histologically and biochemically, although other strategies have been described with limited or no success. We herein review the mechanisms of disease recurrence and the current as well as the future therapeutic approaches to prevent and to treat these diseases.

Original languageEnglish (US)
Pages (from-to)691-701
Number of pages11
JournalArchives of Medical Research
Volume38
Issue number6
DOIs
StatePublished - Aug 1 2007

Fingerprint

Virus Diseases
Hepatitis C
Hepatitis B
Liver Transplantation
Liver Diseases
Recurrence
Transplants
End Stage Liver Disease
Ribavirin
Liver
Nucleosides
Interferons
Immunoglobulins
Hepatocellular Carcinoma
Nucleotides
Viruses
Therapeutics

Keywords

  • Hepatitis B
  • Hepatitis C
  • Liver reinfection
  • Liver transplant

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Recurrent Viral Liver Disease (Hepatitis B and C) after Liver Transplantation. / Olivera-Martínez, Marco Antonio; Gallegos-Orozco, Juan F.

In: Archives of Medical Research, Vol. 38, No. 6, 01.08.2007, p. 691-701.

Research output: Contribution to journalReview article

@article{58b1c2a765bf42e785ab0dee43e16134,
title = "Recurrent Viral Liver Disease (Hepatitis B and C) after Liver Transplantation",
abstract = "Hepatitis C represents more than 35{\%} of liver transplant candidates worldwide. Meanwhile, hepatitis B continues to be an important cause of end-stage liver disease and hepatocellular carcinoma in Asia and Africa. Recurrent viral liver disease is a significant event after liver transplantation and continues to be one of the main causes of graft dysfunction and loss in the middle and long-term follow-up. Mechanisms of liver reinfection and disease recurrence vary between these two viruses and pre-emptive as well as the therapeutic approaches are different. Hepatitis B patients can be managed with immune globulin immediately after liver transplant and various agents such as nucleotide and nucleoside analogues can be associated. As a result, disease recurrence has been delayed or prevented in these patients. Individuals transplanted for hepatitis C are known to have universal reinfection and a high rate of disease recurrence has been reported in the literature. Strategies to treat hepatitis C recurrence are limited to the use of pegylated interferon and ribavirin when disease is demonstrated histologically and biochemically, although other strategies have been described with limited or no success. We herein review the mechanisms of disease recurrence and the current as well as the future therapeutic approaches to prevent and to treat these diseases.",
keywords = "Hepatitis B, Hepatitis C, Liver reinfection, Liver transplant",
author = "Olivera-Mart{\'i}nez, {Marco Antonio} and Gallegos-Orozco, {Juan F.}",
year = "2007",
month = "8",
day = "1",
doi = "10.1016/j.arcmed.2006.09.003",
language = "English (US)",
volume = "38",
pages = "691--701",
journal = "Archives of Medical Research",
issn = "0188-4409",
publisher = "Elsevier Inc.",
number = "6",

}

TY - JOUR

T1 - Recurrent Viral Liver Disease (Hepatitis B and C) after Liver Transplantation

AU - Olivera-Martínez, Marco Antonio

AU - Gallegos-Orozco, Juan F.

PY - 2007/8/1

Y1 - 2007/8/1

N2 - Hepatitis C represents more than 35% of liver transplant candidates worldwide. Meanwhile, hepatitis B continues to be an important cause of end-stage liver disease and hepatocellular carcinoma in Asia and Africa. Recurrent viral liver disease is a significant event after liver transplantation and continues to be one of the main causes of graft dysfunction and loss in the middle and long-term follow-up. Mechanisms of liver reinfection and disease recurrence vary between these two viruses and pre-emptive as well as the therapeutic approaches are different. Hepatitis B patients can be managed with immune globulin immediately after liver transplant and various agents such as nucleotide and nucleoside analogues can be associated. As a result, disease recurrence has been delayed or prevented in these patients. Individuals transplanted for hepatitis C are known to have universal reinfection and a high rate of disease recurrence has been reported in the literature. Strategies to treat hepatitis C recurrence are limited to the use of pegylated interferon and ribavirin when disease is demonstrated histologically and biochemically, although other strategies have been described with limited or no success. We herein review the mechanisms of disease recurrence and the current as well as the future therapeutic approaches to prevent and to treat these diseases.

AB - Hepatitis C represents more than 35% of liver transplant candidates worldwide. Meanwhile, hepatitis B continues to be an important cause of end-stage liver disease and hepatocellular carcinoma in Asia and Africa. Recurrent viral liver disease is a significant event after liver transplantation and continues to be one of the main causes of graft dysfunction and loss in the middle and long-term follow-up. Mechanisms of liver reinfection and disease recurrence vary between these two viruses and pre-emptive as well as the therapeutic approaches are different. Hepatitis B patients can be managed with immune globulin immediately after liver transplant and various agents such as nucleotide and nucleoside analogues can be associated. As a result, disease recurrence has been delayed or prevented in these patients. Individuals transplanted for hepatitis C are known to have universal reinfection and a high rate of disease recurrence has been reported in the literature. Strategies to treat hepatitis C recurrence are limited to the use of pegylated interferon and ribavirin when disease is demonstrated histologically and biochemically, although other strategies have been described with limited or no success. We herein review the mechanisms of disease recurrence and the current as well as the future therapeutic approaches to prevent and to treat these diseases.

KW - Hepatitis B

KW - Hepatitis C

KW - Liver reinfection

KW - Liver transplant

UR - http://www.scopus.com/inward/record.url?scp=34347214442&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34347214442&partnerID=8YFLogxK

U2 - 10.1016/j.arcmed.2006.09.003

DO - 10.1016/j.arcmed.2006.09.003

M3 - Review article

C2 - 17613360

AN - SCOPUS:34347214442

VL - 38

SP - 691

EP - 701

JO - Archives of Medical Research

JF - Archives of Medical Research

SN - 0188-4409

IS - 6

ER -